MYLOTARG is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients aged 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL)1
NICE2 and SMC3 have approved MYLOTARG as an option in this indication for patients with favourable, intermediate or unknown cytogenetics and can be initiated whilst awaiting cytogenetic or molecular testing results
MYLOTARG is indicated for first-line use in de novo CD33-postive AML, except APL1
From Day 1
MYLOTARG can be initiated from Day 1 whilst awaiting cytogenetic or molecular testing results4
Across patient subgroups
MYLOTARG demonstrates improved EFS across a range of patient subgroups (including mutation and risk status) vs standard of care.4 MYLOTARG did not demonstrate improved EFS in adverse risk cytogenetics.4
Click below for dosing, schedule and administration information including Pharmacy and Dosing Guides available to download
Click here to view event-free survival (EFS) data by cytogenetic profile
Watch Dr. Sreetharan Munisamy discuss the current treatment landscape for de novo AML in Video 1 of the Key Topics in the Management of de novo AML video series.
Click the link below to explore the rest of the on-demand series.
Watch Professor Robert Hills discuss the key clinical data from the pivotal ALFA-0701 study.
AML, Acute Myeloid Leukaemia; DGH, District General Hospital; EFS, event-free survival; NICE, National Institute for Health and Care Excellence; SMC, Scottish Medicines Consortium
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021